MSH release-inhibiting factor

Melanocyte stimulating hormone release inhibiting factor is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: R1833

CAS No:2002-44-0

Synonyms/Alias:2002-44-0;MELANOSTATIN;MIF-1;L-Prolyl-L-leucylglycinamide;Oxytocin C-terminal tripeptide;Pro-Leu-Gly-NH2;MIF-I;7-9-Oxytocin;Melanostatin I (ox);(S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide;Prolylleucylglycine amide;MSH-release inhibiting factor I;C13H24N4O3;(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide;L-Prolyl-L-leucylglycylamide;Glycinamide, L-prolyl-L-leucyl-;L-Proline-L-leucine-glycine-amide;CHEMBL317488;3KY24B4Q62;(2S)-N-(carbamoylmethyl)-4-methyl-2-{[(2S)-pyrrolidin-2-yl]formamido}pentanamide;Pro-Leu-Gly amide;UNII-3KY24B4Q62;Prolyl-L-leucyl-glycinamide, L-;EINECS 217-902-7;L-pro-L-leu-gly-NH2;MELANOSTATIN MIF-I;SCHEMBL362530;MELANOSTATIN MIF-I [MI];DTXSID20173841;CHEBI:168693;NOOJLZTTWSNHOX-UWVGGRQHSA-N;MIF-I, (-)-;BBL033793;BDBM50060601;HB1874;MFCD00037866;MFCD08282654;STL372235;2-Pyrrolidinecarboxamide, N-(1-((carbamoylmethyl)carbamoyl)-3-methylbutyl)-;AKOS015955826;MSH RELEASE-INHIBITING FACTOR I;(2S)-N-(carbamoylmethyl)-4-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanamide;(S)-N-((S)-1-(2-amino-2-oxoethylamino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide;DA-66890;FM109235;NS-04720;PD070730;HY-107663;CS-0029128;NS00026500;EN300-302728;6-((E)-3-Oxo-3-phenyl-propenyl)-1H-pyrimidine-2,4-dione;(E)-6-(3-oxo-3-phenylprop-1-enyl)pyrimidine-2,4(1H,3H)-dione;(S)-Pyrrolidine-2-carboxylic acid [(S)-1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide;Pyrrolidine-2-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide;

Chemical Name:(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C13H24N4O3
M.W/Mr.
284.35
Sequence
One Letter Code:PLG
Three Letter Code:H-Pro-Leu-Gly-NH2
Long-term Storage Conditions
≥59.1mg/mL in DMSO
Shipping Condition
Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.
InChI
InChI=1S/C13H24N4O3/c1-8(2)6-10(12(19)16-7-11(14)18)17-13(20)9-4-3-5-15-9/h8-10,15H,3-7H2,1-2H3,(H2,14,18)(H,16,19)(H,17,20)/t9-,10-/m0/s1
InChI Key
NOOJLZTTWSNHOX-UWVGGRQHSA-N
Canonical SMILES
CC(C)CC(C(=O)NCC(=O)N)NC(=O)C1CCCN1
Isomeric SMILES
CC(C)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Epitope Mapping ServicesPeptide Synthesis ServicesCustom Conjugation ServicePeptide Modification ServicesPeptide Analysis ServicescGMP Peptide ServicePeptide CDMOPeptide Nucleic Acids Synthesis
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers